Genelux Corp Stock Price, News & Analysis

Genelux (NASDAQ: GNLX) has announced the dosing of the first patient in its U.S.-based Phase 2 (VIRO-25) trial. This trial aims to evaluate the efficacy and safety of systemically delivered Olvi-Vec in patients with recurrent non-small cell lung cancer (NSCLC) who have failed frontline platinum and immune checkpoint inhibitor (ICI) therapies.

The VIRO-25 trial (NCT06463665) is an open-label, randomized study comparing Olvi-Vec followed by platinum-doublet chemotherapy + Physician's Choice of ICI to docetaxel. This marks the second indication for Olvi-Vec via systemic administration in the clinic. Genelux expects an interim data readout in mid-2025.

The company's CEO, Thomas Zindrick, emphasized the significance of this milestone for NSCLC patients with therapeutic options. This trial, along with an ongoing Phase 1b/2 trial in recurrent small cell lung cancer, positions Olvi-Vec as a potential systemically administered oncolytic virus treatment option.

Genelux (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The event is scheduled to take place from October 15-17, 2024.

Thomas Zindrick, President, CEO, and Chairman of the Board of Genelux, will engage in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim. The discussion is set for October 15, 2024, at 2:00 pm E.T.

During the chat, Zindrick will provide insights into Genelux's clinical-stage programs, recent announcements, and upcoming milestones. This presentation offers an opportunity for investors and interested parties to gain valuable information about Genelux's progress and future plans in the immuno-oncology field.

Genelux (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the H.C. Wainwright Global Healthcare Conference from September 9-11, 2024, in New York City. Thomas Zindrick, President, Chairman and CEO, will engage in a fireside chat with Emily Bodnar, Vice President of Equity Research and H.C. Wainwright Biotechnology Analyst, on September 11 at 12:30 p.m. ET.

The presentation will cover Genelux's clinical-stage programs, recent announcements, and upcoming milestones. A webcast of the event will be available, with an archived replay accessible for approximately 90 days on the company's IR page. Genelux will also participate in virtual one-on-one meetings during the conference, offering institutional investors the opportunity to engage directly with management.

Genelux (NASDAQ: GNLX) reported its Q2 2024 financial results and provided business updates. The company completed a $30 million public offering, providing runway through three trial readouts. Genelux anticipates interim results from the Phase 2 trial in recurrent non-small cell lung cancer by mid-2025 and interim data from the Phase 1b trial in recurrent small cell lung cancer later this year. The ongoing Phase 3 OnPrime/GOG-3076 trial in platinum-resistant/refractory ovarian cancer continues enrollment with topline results expected in H2 2025.

Financial highlights include:

• Cash, cash equivalents, and investments of $40.4 million as of June 30, 2024
• R&D expenses increased to $4.4 million in Q2 2024
• G&A expenses remained flat at $2.5 million
• Net loss of $6.6 million or $0.22 per share

Genelux (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in BTIG's Virtual Biotechnology Conference 2024. The company's President, CEO, and Chairman, Thomas Zindrick, will engage in a fireside chat with Kaveri Pohlman, PhD, Director and BTIG Biotechnology Analyst. The discussion is scheduled for Tuesday, August 6, 2024, at 12:00 p.m. ET.

During the chat, Zindrick will provide insights into Genelux's clinical-stage programs, recent announcements, and upcoming milestones. This event presents an opportunity for investors and industry professionals to gain valuable information about Genelux's progress and future plans in the immuno-oncology field.

Genelux (Nasdaq: GNLX), an immuno-oncology company, has announced the pricing of an underwritten offering of 6,875,000 shares of common stock and accompanying warrants at $4.00 per share and warrant. Each warrant will have an exercise price of $5.25. The gross proceeds are expected to be approximately $27.5 million, with net proceeds providing working capital into Q1 2026. The funds will support the clinical development of Olvi-Vec, with Phase 3 trial results anticipated in H2 2025. The offering is expected to close around May 29, 2024. Guggenheim Securities and Newbridge Securities are managing the offering. A 30-day option for an additional 1,031,250 shares and warrants is also included.

Genelux (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, has announced a proposed public offering of its common stock and accompanying warrants. This offering is underwritten, with Guggenheim Securities acting as the sole book-running manager and Newbridge Securities as the co-manager. Genelux plans to grant underwriters a 30-day option to purchase an additional 15% of the shares sold.

The offering is backed by an effective shelf registration statement filed with the SEC, and a preliminary prospectus supplement will be filed. The completion of the offering is subject to market conditions and other customary closing conditions.

Genelux reported its first-quarter 2024 financial results and provided updates on its business activities. The company is progressing with its pivotal Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer and plans to expand its use into other cancer indications. Genelux is also enrolling patients in clinical trials for non-small cell lung cancer and recurrent small cell lung cancer. The company filed a shelf registration statement to offer up to $300.0 million in common stock, preferred stock, debt securities, and warrants. Financially, Genelux had $19.6 million in cash, cash equivalents, and short-term investments as of March 31, 2024. Research and development expenses increased by $1.2 million year-over-year, while general and administrative expenses increased by $0.3 million in the first quarter of 2024.